Depression News

ORLANDO — A home-based mental health program for individuals with epilepsy was effective in detecting symptoms of depression and suicidality, according to a poster.

The U.S. has issued patents covering several advances in psychedelic therapy, including the “world’s first” new forms of psilocybin and orally active DMT and 5-MeO-DMT, according to a press release from the manufacturer.

Isotretinoin is not associated with an increased risk for suicide or psychiatric conditions on a population level, according to a study.

ORLANDO — Among individuals with epilepsy, the prevalence of a major depressive disorder diagnosis was almost doubled compared with generalized anxiety disorder and varied by type of antiseizure medication used, according to a poster.

The investigational antidepressant ALTO-300 demonstrated clinically meaningful improvements in patients with major depressive disorder, particularly among those characterized by a biomarker, according to a manufacturer press release.

Among women in China, depressive symptoms during pregnancy were associated with slower fetal growth rate in the rapid growth stage during weeks 30 and 37 of gestation, according to study findings published in JAMA Network Open.

ORLANDO — Self-managing programs to address comorbidities in patients with epilepsy require more education and independence from the creators, according to a poster.

ORLANDO — Caregivers of patients in the U.K. with Dravet syndrome would benefit from better communication, access to health care and increased psychosocial interventions, per a poster at the American Epilepsy Society annual meeting.

With potential FDA approvals on the horizon, the controversy surrounding psychedelics in clinical practice may soon reach a tipping point, according to experts.

The FDA has issued a warning against the purchase or use of products that contain tianeptine, which has been illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.